ODB Funded (tablets, oral liquid)

• >10%: Gastrointestinal: Diarrhea (16%)
• 2% to 10%: Gastrointestinal: Abdominal pain, nausea, dyspepsia, flatulence, loose stools
• <2%: Acute renal failure, anaphylactoid reaction, anaphylaxis, angioedema, candidiasis, dizziness, drug fever, eosinophilia, erythema multiforme, facial edema, fever, headache, hepatitis, hyperbilirubinemia, increased blood urea nitrogen, increased serum creatinine, increased serum transaminases, jaundice, leukopenia, neutropenia, prolonged prothrombin time, pruritus, pseudomembranous colitis, seizure, serum sickness-like reaction, skin rash, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria, vaginitis, vomiting

• With prolonged therapy, monitor renal and hepatic function periodically; number and type of stools/day for diarrhea
• Observe for signs and symptoms of anaphylaxis during first dose
• When used as part of alternative treatment for gonococcal infection, test-of-cure 7 days after dose (CDC 2012)